The threat of enforcement from a patent holder and the ensuing litigation costs has created a chilling effect on clinical laboratories producing us reluctant to build up new exams that could directly benefit patients.’ The duty force drafting the statement represented the full spectrum of stakeholders and completed a very transparent process with unlimited opportunities for public comment. The ultimate report is usually articulate and authoritative, and provides a balanced assessment of the results of DNA patents.Evaluation of endogenous SALL4 expression across a panel of 10 human being hepatocellular carcinoma cell lines through a quantitative polymerase-chain-response assay showed the expression of SALL4 at various levels, reflecting the expression pattern seen in the hepatocellular carcinoma cells specimens described above . Furthermore, SALL4 expression had not been detected in the two immortalized, nontransformed liver-cell lines, THLE-3 and THLE-2. These data claim that these cell lines work models for further testing of our hypothesis and confirm our finding that SALL4 is certainly reexpressed in a subgroup of hepatocellular carcinomas.